Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aliskiren

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    83 result(s) found for: Aliskiren. Displaying page 4 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2008-007831-41 Sponsor Protocol Number: CSPP100A2408 Start Date*: 2009-04-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A twelve-week, randomized, double-blind, parallel group study to evaluate the prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patien...
    Medical condition: hypertension
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) ES (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010170-38 Sponsor Protocol Number: CSPP100G2301 Start Date*: 2010-07-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO)
    Medical condition: cardiovacular disease, fonctional hypertension,
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020772 Hypertension LLT
    12.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) DE (Completed) IE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005500-10 Sponsor Protocol Number: CSPP100A2406 Start Date*: 2008-12-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An eight-week, randomized, double-blind, parallel-group, pilot study to evaluate the efficacy and safety of aliskiren 300 mg in comparison with valsartan 320 mg in patients with mild to moderate hy...
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001440-22 Sponsor Protocol Number: 831 Start Date*: 2019-07-28
    Sponsor Name:Skåne University Hospital
    Full Title: Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting ...
    Medical condition: C3 glomerulopathy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005216-40 Sponsor Protocol Number: CSPA100A2306 Start Date*: 2008-12-26
    Sponsor Name:Novartis Farmaceutica S.A.
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, de 8 semanas de duración para evaluar la eficacia y seguridad de la combinación de aliskiren 300 mg y amlodipino 10 mg en com...
    Medical condition: hipertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000538-12 Sponsor Protocol Number: HLK-VASC-11/01 Start Date*: 2011-06-14
    Sponsor Name:VU University Medical Center
    Full Title: An exploratory open-label PET-observer-blinded pilot study to evaluate the effect of 3 and 12 months treatment with Aliskeren-based versus amlodipin-based antihypertensive treatment in patients wit...
    Medical condition: Abdominal Aortic Aneurysm Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001242-10 Sponsor Protocol Number: CSAH100A2301 Start Date*: 2008-08-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 28 to 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren / amlodipine / and hydrochlorothiazide in patients with essential hype...
    Medical condition: hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011296-80 Sponsor Protocol Number: CSPP100AFR01 Start Date*: 2009-06-10
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: Efficacy of Rasilez® (Aliskiren) compared to ramipril in the treatment of moderate systolic hypertensive patients
    Medical condition: Hypertension artérielle systolique
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042957 Systolic hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014359-63 Sponsor Protocol Number: CSPA100A2201 Start Date*: 2010-01-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double blind, randomized, parallel study to assess the effects of aliskiren/amlodipine and amlodipine monotherapy on ankle foot volume (AFV) in patients naïve to trial drugs with mild to moderate...
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    M15 10020772 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006447-40 Sponsor Protocol Number: CSPP100A2366 Start Date*: 2009-02-23
    Sponsor Name:Novartis Farmacéutica
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, con grupos paralelos y de 104 semanas de duración, para evaluar la eficacia de aliskiren en la progresión de la aterosclerosis en pacientes con enf...
    Medical condition: Progresión de la aterosclerosis en pacientes con enfermedad arterial coronaria
    Disease: Version SOC Term Classification Code Term Level
    9 10011076 Coronary artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) FR (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017676-24 Sponsor Protocol Number: CSPP100ADE07T Start Date*: 2010-02-26
    Sponsor Name:University Hospital Erlangen
    Full Title: Randomized, double blind, active-controlled, parallel study to analyse effects of the combination of aliskiren and valsartan on the vascular structure and function of retinal vessels
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016077-14 Sponsor Protocol Number: RALF1 Start Date*: 2010-11-11
    Sponsor Name:Mika Lehto
    Full Title: Role of ALiskiren, a direct renin inhibitor, in preventing atrial Fibrillation in patients with a pacemaker; RALF Eteisvärinäkuorman määritys sydämentahdistimella aliskireenihoidossa
    Medical condition: Patients who have a pacemaker due to sinus node disease and paroxysmal atrial fibrillation.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067824 Prophylaxis against atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016902-17 Sponsor Protocol Number: CLINMEDINT001 Start Date*: 2012-05-18
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: Direct renin inhibitor (aliskiren)and carotid plaques instability markers in hypertensive patients requiring carotid endoarterectomy
    Medical condition: Essential hypertension.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059238 LLT
    9.1 10007692 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2010-021987-13 Sponsor Protocol Number: NL29900.04 Start Date*: 2010-10-15
    Sponsor Name:University Medical Center Groningen
    Full Title: Renal Hemodynamic Effects of ALiskiren (rasilez) in comparison to ramipril (Tritrace) in patients with overweigHt/obeSiTy and UntreateD hYpertension: The renal HEALTH-STUDY
    Medical condition: Glomerular hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008287-28 Sponsor Protocol Number: ALI-FRA-0030-I Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Erlangen
    Full Title: Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes
    Medical condition: Patients with prediabetes (either impaired glucose tolerance or imparied fasting glucose) and no obvious diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015600-26 Sponsor Protocol Number: CSPP100ADE05T Start Date*: 2009-12-07
    Sponsor Name:Universitätsklinikum Würzburg
    Full Title: An open label prospective pilot-study to determine the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients wit...
    Medical condition: Determination of the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with coronary artery disease and hype...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10020772 Hypertension PT
    14.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015982-29 Sponsor Protocol Number: UMCU-Vasc-14A Start Date*: 2010-07-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: A randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study the effects of aliskiren, hydrochlorothiazide and moxonidine on endothelial dysfunction in obesity related hyper...
    Medical condition: Hypertension in subjects with abdominal obesity and the metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10059179 Abdominal obesity LLT
    12.1 10052066 Metabolic syndrome LLT
    12.1 10020772 Hypertension LLT
    12.1 10065941 Central obesity LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004242-83 Sponsor Protocol Number: CSPA100A2307 Start Date*: 2008-11-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, 32 week double-blind, parallel-group, multicenter study to compare the efficacy and safety of initiating treatment with combination (aliskiren/amlodipine) therapy in comparison with t...
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004411-22 Sponsor Protocol Number: CSPP100A2365E2 Start Date*: 2012-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, 52 to 104 week extension study to evaluate the long term growth and development of pediatric hypertensive patients 6 – 17 years of age treated previously with aliskiren
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    14.1 10047065 - Vascular disorders 10039834 Secondary hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-010608-27 Sponsor Protocol Number: ANG692 Start Date*: 2009-11-20
    Sponsor Name:MUMC+
    Full Title: A prospective cohort study to investigate the use of alfa V beta 3 integrin scintigraphic imaging with 99mTC-NC100692 to predict scar formation and heart failure after myocardial infarction in pati...
    Medical condition: Myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028596 Myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:51:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA